Organization | Tyme, Inc

Tyme, Inc Report issue

For profit Phase 2

Founded: New York NY United States (2011)

Organization Overview

First Clinical Trial

2016

NCT02796898

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Chief Medical Officer TYME Inc. | Tyme, Inc

Active Ingredients

Drugs in Phase 2 Trials (10)

capecitabine (xeloda) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

methoxsalen (3 trials)

metyrosine (demser) (1 trial)

phenytoin (mesantoin) (3 trials)

sirolimus (rapamune) (3 trials)

sm-88 (2 trials)

tyrosine isomers (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Neuroectodermal Tumors, Primitive, Peripheral (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 10